The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer

被引：1
|
作者：
Tripathy, Sambit [1 ]
机构：
[1] AIIMS, Dept Urol, Bhubaneswar, Odisha, India
来源：
INDIAN JOURNAL OF UROLOGY | 2021年 / 37卷 / 03期
关键词：
D O I：
10.4103/iju.IJU_542_20
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：293 / 294
页数：2
相关论文
共 50 条
  • [31] Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).
    George, Daniel J.
    Khan, Nasreen
    Constantinovici, Niculae
    Khan, Javeed
    Chen, Guifang
    Xu, Julie
    Ortiz, Jorge A.
    Morgans, Alicia K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [32] Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
    Hiroji Uemura
    Hisashi Matsushima
    Kazuki Kobayashi
    Hiroya Mizusawa
    Hiroaki Nishimatsu
    Karim Fizazi
    Matthew Smith
    Neal Shore
    Teuvo Tammela
    Ken-ichi Tabata
    Nobuaki Matsubara
    Masahiro Iinuma
    Hirotsugu Uemura
    Mototsugu Oya
    Tetsuo Momma
    Mutsushi Kawakita
    Satoshi Fukasawa
    Tadahiro Kobayashi
    Iris Kuss
    Marie-Aude Le Berre
    Amir Snapir
    Toni Sarapohja
    Kazuhiro Suzuki
    International Journal of Clinical Oncology, 2021, 26 : 578 - 590
  • [33] Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
    Appukkuttan, Sreevalsa
    Farej, Ryan
    Miles, LaStella
    Purser, Molly
    Wen, Lonnie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (02): : 166 - 174
  • [34] REAL-WORLD STUDY ON DAROLUTAMIDE, ENZALUTAMIDE, AND APALUTAMIDE FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS USING A UROLOGY NETWORK IN THE UNITED STATES (DEAR STUDY)
    Shore, Neal D.
    Khan, Nasreen
    Constantinovici, Niculae
    Khan, Javeed
    Chen, Guifang
    Xu, Julie
    Ortiz, Jorge
    Morgans, Alicia K.
    George, Daniel J.
    JOURNAL OF UROLOGY, 2023, 209 : E386 - E387
  • [35] Impact of Darolutamide on Local Symptoms in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 11 - 12
  • [36] IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Shore, Neal
    Stenzl, Arnulf
    Pieczonka, Christopher
    Klaassen, Zachary
    Aronson, William
    Karsh, Lawrence
    Ryan, Charles
    Miskic, Marina
    Srinivasan, Shankar
    Mohamed, Ateesha
    Verholen, Frank
    JOURNAL OF UROLOGY, 2021, 206 : E586 - E587
  • [37] Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS.
    Fizazi, Karim
    Shore, Neal D.
    Smith, Matthew Raymond
    Ramos, Rodrigo
    Jones, Robert J.
    Niegisch, Guenter
    Vjaters, Egils
    Ortiz, Jorge A.
    Liang, Steve
    Wang, Yuan
    Srinivasan, Shankar
    Sarapohja, Toni
    Verholen, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
    Mori, Keiichiro
    Mostafaei, Hadi
    Pradere, Benjamin
    Motlagh, Reza Sari
    Quhal, Fahad
    Laukhtina, Ekaterina
    Schuettfort, Victor M.
    Abufaraj, Mohammad
    Karakiewicz, Pierre I.
    Kimura, Takahiro
    Egawa, Shin
    Shariat, Shahrokh F.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (11) : 1892 - 1900
  • [39] Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.
    Smith, Matthew Raymond
    Fizazi, Karim
    Tammela, Teuvo L. J.
    Cruz, Felipe Melo
    Nordquist, Luke T.
    Aleman Polanco, Diana Sofia
    Emmenegger, Urban
    Silveira, Glauco Costa
    Concepcion, Raoul S.
    Paula, Adriano
    de Mendonca Beato, Carlos Augusto
    Fleshner, Neil
    Richardet, Martin Eduardo
    Kuss, Iris
    Le Berre, Marie-Aude
    Borghesi, Gustavo
    Sarapohja, Toni
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [40] Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
    Keiichiro Mori
    Hadi Mostafaei
    Benjamin Pradere
    Reza Sari Motlagh
    Fahad Quhal
    Ekaterina Laukhtina
    Victor M. Schuettfort
    Mohammad Abufaraj
    Pierre I. Karakiewicz
    Takahiro Kimura
    Shin Egawa
    Shahrokh F. Shariat
    International Journal of Clinical Oncology, 2020, 25 : 1892 - 1900
12345